| (±)-JQ1 |
2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F] [1,2,4]三唑并[4,3-A][1,4]二氮杂-6-基)乙酸叔丁酯 |
1268524-69-1 |
| IPI 145 |
IPI-145 |
1201438-56-3 |
| IC86621 |
1-(2-羟基-4-N-吗啉基苯基)乙酮 |
404009-40-1 |
| HA 130 |
HA 130,自分泌运动抑制剂 |
1229652-21-4 |
| GSK2636771 |
GSK2636771 |
1372540-25-4 |
| GSK 2334470 |
GSK2334470 |
1227911-45-6 |
| GSK-2126458 |
GSK2126458 |
1086062-66-9 |
| GDC-0032 |
GDC 0032 |
1282512-48-4 |
| 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione |
3-(5-氟-1H-吲哚-3-基)-2,5-吡咯烷二酮 |
198474-05-4 |
| Fananserin |
法南色林 |
127625-29-0 |
| Tazemetostat (EPZ-6438) |
EPZ-6438 |
1403254-99-8 |
| D-LUCIFERIN POTASSIUM SALT |
D-荧光素钾盐 |
115144-35-9 |
| DL-THIORPHAN |
3-巯基-2苄基丙基甘氨酸 |
76721-89-6 |
| BKM120 (NVP-BKM120, Buparlisib) |
BKM-120 |
944396-07-0 |
| I-BET151 (GSK1210151A) |
7-(3,5-二甲基异噁唑-4-基)-8-甲氧基-1-((R)-1-(吡啶-2-基)乙基)-1H-咪唑并[4,5-C]喹啉-2(3H)-酮 |
1300031-49-5 |
| 1-(2,4-DICHLOROPHENYL)-5-(4-IODOPHENYL)-4-METHYL-N-4-MORPHOLINYL-1H-PYRAZOLE-3-CARBOXAMIDE |
1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-吗啉-1H-吡唑-3-甲酰胺 |
202463-68-1 |
| 2-(3,4-DICHLOROPHENYL)-N-METHYL-N-[(1S)-1-PHENYL-2-(1-PYRROLIDINYL)ETHYL]ACETAMIDE HYDROCHLORIDE |
化合物 T22849 |
115199-84-3 |
| NVP-BGJ398 |
FGFR抑制剂(NVP-BGJ398) |
872511-34-7 |
| 1-Cyclopentyl-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-6-(4-(MorpholinoMethyl)phenyl)-1H-indazole-4-carboxaMide |
EPZ005687 |
1396772-26-1 |
| 2'-cyano-2'-deoxyarabinofuranosylcytosine |
CNDAC HCL SALT |
134665-72-8 |
